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Abstract  1 
 2 
Background and aims: Familial hypercholesterolaemia (FH) is widely underdiagnosed. 3 
Cascade testing (CT) of relatives has been shown to be feasible, acceptable and cost-effective 4 
in the UK, but requires a supply of index cases. Feasibility of universal screening (US) at age 5 
1-2 years was recently demonstrated. We examined whether this would be a cost-effective 6 
adjunct to CT in the UK, given the current and plausible future undiagnosed FH prevalence. 7 
 8 
Methods: Seven cholesterol and/or mutation-based US ± reverse cascade testing (RCT) 9 
alternatives were compared with no US in an incremental analysis with a healthcare 10 
perspective. A decision model was used to estimate costs and outcomes for cohorts exposed 11 
to the US component of each strategy. RCT case ascertainment was modelled using recent 12 
UK CT data, and probabilistic Markov models estimated lifetime costs and health outcomes 13 
for the cohorts screened under each alternative. 1,000 Monte Carlo simulations were run for 14 
each model, and average outcomes reported.  Further uncertainty was explored 15 
deterministically. Threshold analysis investigated the association between undiagnosed FH 16 
prevalence and cost-effectiveness.  17 
 18 
Results: A strategy involving cholesterol screening followed by diagnostic genetic testing and 19 
RCT was the most cost-effective modelled (incremental cost-effectiveness ratio (ICER) 20 
versus  no US £12,480/quality adjusted life year (QALY); probability of cost-effectiveness 21 
96·8% at £20,000/QALY threshold). Cost-effectiveness was robust to both deterministic 22 
sensitivity analyses and threshold analyses that modelled ongoing case ascertainment at 23 
theoretical maximum levels.    24 
 25 
Conclusions: These findings support implementation of universal cholesterol screening 26 
followed by diagnostic genetic testing and RCT for FH, under a UK conventional 27 
willingness-to-pay threshold. 28 
 29 
 30 
 31 
 32 
Key words Hyperlipoproteinaemia type II, systematic population screening, cost-33 
effectiveness   34 
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Introduction 1 
Familial hypercholesterolaemia (FH) is characterised by elevated low-density lipoprotein 2 
cholesterol (LDL-C) from birth, and is associated with elevated risk of coronary heart disease 3 
(CHD).1 A recent general population study described  an odds of CHD for the average 4 
untreated FH phenotype around 13-fold higher than that of the non-FH phenotype.2 This 5 
relative risk is age-dependent, being higher in younger age-groups.3 Mortality at <30 years is 6 
typical of untreated homozygous disease,4 whereas the heterozygous genotype confers 7 
approximately 50% risk of CHD by 50 years among males, and 30% risk of CHD by 60 years 8 
in females.5 6 Recent prevalence estimates for heterozygous disease range from 1/250-1/200 9 
(1/300,000-1/160,000 for homozygous disease).7 8 It is therefore anticipated that there are 10 
approximately 187,500-328,200 people with FH in the UK, but estimates suggest fewer than 11 
15% have been diagnosed.9 10 Those undiagnosed represent a substantial reservoir of 12 
potentially modifiable cardiovascular disease (CVD) risk. 13 
 14 
The aim of FH treatment is LDL-C reduction via lifestyle modification and lipid modifying 15 
therapy (LMT). Limited trial data has constrained treatment at young ages, but recent studies 16 
support early intervention. Legacy effects from statin trials indicate greater treatment benefit 17 
with earlier initiation.11 Young people with treated FH exhibit longer event-free survival than 18 
their affected parents, who experienced relative delay to statin therapy;12 and recent trials 19 
have demonstrated statin impact on carotid intima-media thickness (a measure of carotid 20 
atherosclerosis) in childhood, with younger age of therapy initiation associated with more 21 
limited atherosclerotic progression.13 Although only short term efficacy and safety data are 22 
available,14 15 the data supporting early treatment, the premature, often unheralded 23 
consequences of FH, and widespread under-diagnosis,9 have led to recommendations for 24 
screening and early treatment.9 16  25 
 26 
Since 2008, the UK National Institute for Health and Care Excellence (NICE) has 27 
recommended cascade testing (CT, of first-, second- and third- degree relatives) for FH,16  28 
and this has been shown to be feasible, acceptable and cost-effective.17 18 There has been 29 
limited roll-out of CT in England, as local teams have not commissioned the relevant 30 
services, but it has been relatively successful in other parts of the UK.19 As CT depends on 31 
index case supply, there is interest in screening to identify index cases.  Both adult and 32 
childhood systematic population screening (or ‘universal screening’; US) for FH remain 33 
under review by the UK National Screening Committee (NSC). Recent NSC external review 34 
has considered that the NHS Health Check may represent an adulthood FH screening 35 
mechanism,20 but we are unaware of data supporting this. Moreover, the reach of Health 36 
Checks is restricted and increasingly so under the current contraction of UK local public 37 
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health budgets.21 22 Feasibility of otherwise screening in adulthood has not been demonstrated, 1 
and no model for adult screening has been described. There are also theoretical reasons to 2 
favour screening in childhood. The false positive and false negative FH case detection rates 3 
for given cholesterol thresholds appear to be most favourable at young ages,23 and screening 4 
at younger ages enables intervention at an early stage of atherosclerosis development, when 5 
maximum benefit can still be obtained via lifestyle adaptations and LMT. The feasibility of 6 
US at age 1-2 years has recently been demonstrated,24 but cost-effectiveness is unclear.   7 
 8 
We therefore aimed to determine whether US for FH at 1-2 years could be a cost-effective 9 
adjunct to CT in the UK. Our main objective was to compare the cost-effectiveness of 10 
cholesterol and/or mutation-based US ± reverse cascade testing (RCT; where feasible) 11 
alternatives (detailed in Box 1), at current undiagnosed FH prevalence. We also examined 12 
whether there would be a point at which US would lose cost-effectiveness (due to falling FH 13 
prevalence as a result of screening and CT). 14 
 15 
 16 
 17 
 18 
 19 
 20 
  21 
Box 1: Universal screening alternatives considered 
 
1. No universal screening (allows for any ongoing cluster testing) 
2. Cholesterol screening 
3. Sequential genetic testing-cholesterol screening (i.e. genetic testing followed by cholesterol 
screening among mutation-positive individuals) 
4. Sequential cholesterol screening-genetic testing (i.e. cholesterol screening followed by genetic 
testing among cholesterol-positive individuals) 
5. Parallel cholesterol screening–genetic testing (i.e. cholesterol screening coincident with genetic 
testing) 
6-8. Comparators 3-5, respectively, plus reverse cascade testing 
 
NB. It was assumed all strategies would include assessment against clinical diagnostic criteria, hence only 
comparator two would result in some individuals being partially tested against standard UK diagnostic criteria and at 
risk of false positive results 
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Materials and methods 1 
 2 
Comparators, approach and perspective 3 
The alternatives described in Box 1 were compared (with reference to heterozygous FH only) 4 
from a UK NHS healthcare perspective. Methods were aligned with the NICE reference case 5 
so far as possible,25 in an incremental analysis that estimated lifetime (to a maximum of 100 6 
years) costs and health outcomes (discounted at 3·5% per annum) for cohorts screened under 7 
each alternative. Where possible, modelling was based on UK data, and UK diagnostic 8 
criteria and treatment pathways. In the base case, definition of FH (for treatment purposes) 9 
was therefore a Simon Broome diagnosis plus hypercholesterolaemia (defined as total 10 
cholesterol exceeding the general population 95th percentile).26 27 All (and only) mutation-11 
positive individuals were considered as index individuals for RCT.  12 
 13 
The model had three main components: 14 
 15 
1. A decision tree estimated outcomes for cohorts of 10,000 1-2 year olds exposed to the 16 
US component of each alternative 17 
2. Local CT data were used to estimate RCT case ascertainment, given the number of 18 
mutation-positive individuals identified in US, and 19 
3. Markov models estimated lifetime costs and health outcomes for the cohorts screened 20 
under each alternative, in view of the number of diagnoses made 21 
 22 
Data for parameter estimation were obtained from a systematic review (published 2000),26 23 
updated with a systematic literature search (detailed in Supplementary File 1) and data from a 24 
recent economic evaluation and the Welsh FH CT programme (personal communication).17 25 
As relevant data were sparse, no formal syntheses were undertaken and model parameters 26 
were estimated conservatively. 27 
 28 
Model structure and inputs 29 
The decision tree used to model US (Figure 1a) reflects simplified versions of the screening 30 
pathway used in the recent UK study that demonstrated US feasibility.24 The associated 31 
probabilities (Table 1) were combined to derive outcomes for each screening cohort 32 
(Supplementary File 2). We assumed there was no delay between US case-identification and 33 
RCT, and based on local data and an expectation that a US programme would facilitate 34 
improved CT,24 28 estimated base case RCT yield was two mutation-positive individuals per 35 
mutation-positive index individual. That is, where RCT was part of the screening alternative 36 
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it was assumed two mutation-positive individuals would be identified via RCT for every 1 
mutation-positive individual identified in US. It was assumed the age-distribution of those 2 
identified by RCT would be as observed in the Welsh CT programme,17 and that 70% of 3 
RCT-identified mutation-positive relatives would meet the base case FH definition.29-31 For 4 
purposes of costing RCT (see below), probability of mutation detection among relatives was 5 
assumed to be Mendelian. 6 
 7 
Separate Markov models estimated outcomes for cohorts of 1,000 diagnosed or undiagnosed 8 
individuals, starting from age two years, five years, and each subsequent five-year interval to 9 
85 years. The modelling approach followed that used in the economic evaluation for NICE 10 
CG181, and a recent CT analysis, and is described fully in Supplementary File 3.17 32 Briefly, 11 
baseline CVD risks drew on the QRISK2 model,33 and the modelled health states included all 12 
constituent diagnoses of the QRISK outcome (see Figure 1b). Where QRISK2 was not 13 
validated for age-groups of interest, CVD risks were estimated using age-related CVD 14 
relative risks calculated from published data.34 The relative CHD death risks described for the 15 
pre-treatment era Simon Broome cohort were applied to the angina, MI and CHD death risks.3 16 
Individuals progressed to post-CVD states in the cycle following development of non-fatal 17 
CVD, unless a further event or death occurred immediately. Secondary event risks obtained 18 
from NICE CG181 (with some adjustments – see Supplementary File 3) were applied without 19 
adjustment for FH,32 but the models did not allow for impact of multiple previous events. 20 
Non-CVD mortality was estimated from 2015 England and Wales Office for National 21 
Statistics mortality and mid-year population figures,35 36 and it was assumed that CVD and 22 
mortality risks for the youngest age-group (not specifically reported), were zero. Modelled 23 
treatment was based on national guidance and local audit and registry data, and was modelled 24 
until age 60 years (details in Supplementary File 4).10 16 37 Welsh FH audit age-band-specific 25 
pre-treatment LDL-C levels (concordant with national paediatric register data) were applied,17 26 
and 37% treatment-related LDL-C reduction modelled in the base case (as observed in the 27 
UK 2010 national FH audit,10 cf. 35% in paediatric register).37 Resultant expected treatment-28 
related absolute LDL-C reductions were transformed to CVD relative risk reductions using 29 
the Cholesterol Treatment Trialists’ (CTT) Collaboration-reported per mM values for non-30 
fatal MI, ischaemic stroke, and CHD death (applied to angina and MI, TIA and stroke, and 31 
CHD death, risks, respectively).38 The CTT values were assumed applicable to both primary 32 
and secondary events. 33 
 34 
Cycle health state outcomes were weighted with the utilities described in CG181,32 and costs 35 
and effects were discounted, enabling calculation of discounted quality-adjusted life year 36 
(QALY) and cost outcomes for each model. Models assumed no FH- or LMT- associated 37 
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disutility, as per previous observation,39 40 and assumption that treatment-related disutility 1 
would prompt treatment modification, averting its persistence. To determine overall Markov 2 
model outcomes for each alternative, the outcomes from each model were combined 3 
according to the age-distribution and diagnosed/undiagnosed status of the individuals 4 
identified by US and RCT in at least one of the screening scenarios, for each alternative. 5 
 6 
Resource use and costs 7 
Costs were calculated in 2017 GBP. Modelled costs were current where possible, otherwise 8 
inflated to 2017 values, and assumed to remain constant (subject to discounting) over the 9 
model duration. Table 2 summarises the costs applied.  Total US costs were estimated for 10 
each cohort by multiplying individual costs*probability of being incurred under the relevant 11 
strategy*10,000. CT costs per index individual were estimated as the costs of index individual 12 
consultation, plus screening costs for identified relatives (based on CG71 CT 13 
recommendations and associated costing template)*the inverse of the probability of a relative 14 
being affected. Patient monitoring costs were applied only when patients were receiving 15 
LMT, except in cases of LMT-naïve individuals <18 years. At all ages, annual monitoring 16 
included blood sampling, lipid profile testing, and medical review (secondary care review at 17 
<18 years; 80:20 secondary:primary care split at ≥18 years).10 28 Creatine kinase and 2x liver 18 
function tests were costed for the first treatment year, plus an additional secondary care 19 
review if this was not the screening year. 20 
 21 
Management of uncertainty and calculations 22 
To include parameter uncertainty, Markov models were built probabilistically, with beta 23 
distributions applied for transition probabilities and utilities, log-normal distributions for the 24 
CVD relative risks associated with FH and LDL-C reduction, and normal distribution for the 25 
pre-treatment LDL-C estimates (details in Supplementary File 5). 1,000 Monte Carlo 26 
simulations were run for each model. Uncertainty was further explored in a series of one-way 27 
DSAs, as outlined in Table 3, and the impact of including treatment costs for false positives 28 
identified in the cholesterol-only screening alternative (assuming treatment as per true 29 
positives, with estimated survival based on current standard life tables),41 was also 30 
considered. 31 
 32 
In all analyses, ICERs were calculated for each alternative versus  the next lowest cost. 33 
Dominated comparators were excluded and the remaining alternatives compared to the 34 
remaining next lowest cost, repeated as necessary. Cost-effectiveness was assessed using the 35 
£20,000-£30,000 NICE willingness-to-pay threshold,25 and cost-effectiveness acceptability 36 
curves were plotted. Threshold analysis estimated the undiagnosed FH prevalences at which 37 
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the ICER for the most cost-effective screening strategy crossed £20,000/QALY and 1 
£30,000/QALY willingness-to-pay thresholds, under otherwise base case conditions ± off-2 
patent LMT costs (see Table 3). Scenarios in which CT yields were 2·4, 6·1 and 8·6 3 
cases/index, and undiagnosed FH prevalences were 67, 33 and 24%, respectively, were also 4 
considered, as theoretical analyses indicate that such undiagnosed prevalences could not be 5 
reached with these CT yields.42 Analyses were carried out using MS Excel v14.7.7. 6 
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Results 1 
The sequential cholesterol screening-genetic testing plus RCT strategy was the most cost-2 
effective in all analyses, and no scenario identified an additional strategy that could be cost-3 
effectively provided. The number of FH cases identified under each screening strategy, costs 4 
per diagnosis, average QALYs gained, overall costs, and associated ICERs, are displayed in 5 
Table 4 (DSA estimates in Supplementary Files 6 and 7). Diagnosis rates ranged from 6 
11·4/10,000 screened (sequential genetic testing-cholesterol screening) to 25·4/10,000 7 
(parallel cholesterol screening-genetic testing) without RCT, and 31·1/10,000 to 45·1/10,000 8 
(same US strategies) with RCT. Costs per US diagnosis ranged from £11,788 (cholesterol-9 
only screening) to £217,036 (sequential genetic-cholesterol screening). Cost per RCT 10 
diagnosis was £1,110. The lowest overall cost per diagnosis (£8,886) was observed for the 11 
sequential cholesterol screening-genetic testing plus RCT strategy, which also achieved the 12 
second highest number of diagnoses (39·8/10,000). The ICER for this strategy versus  no 13 
screening (£12,480/QALY) dominated all others except the parallel cholesterol-genetic US 14 
plus RCT scenario (ICER for direct comparison =£399,581/QALY).   15 
 16 
As expected, ICERs were sensitive to RCT success, ranging from £6,269-£6,729/QALY to 17 
£18,253/QALY across the RCT yields tested. Discounting at 1·5%, and 50% treatment-18 
related LDL-C reduction, were associated with relatively low ICERs (£5,489/QALY and 19 
£7,733/QALY, respectively). Only discounting at 5% produced an ICER >£20,000/QALY 20 
(£20,849/QALY). Cost-effectiveness acceptability curves for the sequential cholesterol 21 
screening-genetic testing US plus RCT versus  no screening comparison are displayed for 22 
several scenarios in Supplementary File 8. For the base case, probability of cost-effectiveness 23 
was 96·8% at a willingness-to-pay threshold of £20,000/QALY (100% at £30,000/QALY).      24 
 25 
Threshold analysis suggested US would be cost-effective at a £20,000/QALY threshold until 26 
undiagnosed prevalence reached <48% (<30% for £30,000/QALY threshold). Corresponding 27 
prevalences were <43% and <28% with off-patent LMT costs. ICERs for the scenarios in 28 
which undiagnosed prevalences of 67%, 33% and 24%, and respective CT yields of 2·4, 6·1 29 
and 8·6 cases per index, were modelled, were £13,692/QALY, £14,630/QALY and £15,680-30 
£16,146/QALY, respectively (£11,745/QALY, £12,851/QALY and £13,653-14,115/QALY 31 
with off-patent LMT costs). 32 
 33 
  34 
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Discussion 1 
Summary of findings 2 
This study aimed to assess which of seven potential FH US strategies would be most cost-3 
effective for the UK context, whether any would be cost-effective as per conventional NICE 4 
definition, and whether US could reduce undiagnosed FH prevalence to levels at which it 5 
would lose cost-effectiveness. Sequential cholesterol screening-genetic testing plus RCT was 6 
the most cost-effective alternative modelled, and cost-effectiveness was robust to DSAs and 7 
to reductions in undiagnosed prevalence that US could theoretically achieve.42 The modelled 8 
approach - with screening incorporated into routine child healthcare appointments – is 9 
efficient in terms of minimising user inconvenience, limiting additional healthcare costs, and 10 
potentially promoting screening engagement. As cholesterol results can be obtained by a 11 
point-of-care testing method, individuals with cholesterol levels below the threshold that 12 
would trigger genetic testing could be immediately reassured. While a mutation is only 13 
detected in a proportion of those with LDL-C above the threshold, a mutation confirms the 14 
diagnosis for these individuals, and unequivocal DNA-based diagnostic testing of relatives 15 
(so-called reverse cascade testing) can be undertaken. The clinical value of the approach is 16 
achieved by provision of LMT at a relatively young age, before high LDL-C burden has 17 
resulted in premature atherosclerosis and a CHD event.  18 
 19 
Comparison with existing literature 20 
Among 10,000 children eligible for US, the sequential cholesterol screening-genetic testing 21 
plus RCT strategy we found to be most cost-effective identified fewer children with 22 
hypercholesterolaemia plus an FH mutation (n=10.98) than reported per 10,095 children from 23 
the recent US feasibility study (n=21 such cases identified).24 This may be explained by the 24 
fact that we accounted for non-attendance and non-participation, required 25 
hypercholesterolaemia on two rather than one tests (i.e. accounted for biological and 26 
analytical cholesterol variability), and used a slightly more restrictive definition of 27 
hypercholesterolaemia. Chance may also be relevant as the numbers are small. Reported costs 28 
per diagnosis were lower ($2,900 and £3,500) in recent studies than in our study, but this 29 
discrepancy is expected as in addition to the test costs ± limited consultation time they 30 
considered, we allowed for more screening consultation time (as recommended by local 31 
clinicians familiar with FH testing), administrative costs, and initial specialist review.24,43 We 32 
did not find further recent estimates of diagnosis costs or US cost-effectiveness in children, 33 
but a 2002 HTA estimated both for US at 16 years.26 Comparability is limited by inflation and 34 
methodological differences. Nonetheless, reported costs per diagnosis from the 2002 study 35 
were £9,754 where clinically confirmed and £72,140 with genetic confirmation,26 and the 36 
corresponding costs per life year gained, (with discounting at 3%), £7,244 and £33,882.44 37 
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Given the interim reductions in genetic screening costs, these values probably support that 1 
those reported here are feasible. 2 
 3 
The ICER of £12,480/QALY for sequential cholesterol screening-genetic testing plus RCT is 4 
as expected higher than that recently estimated for CT from known cases (ICER = 5 
£5,806/QALY).17 18 Although several parameters were modelled similarly in both analyses, 6 
the CT analysis did not model identification of index cases,17 18 which depends on testing with 7 
a much lower pre-test probability of disease, and is therefore associated with higher screening 8 
costs per diagnosis. As US enables FH diagnosis at a relatively young age, the differential 9 
latencies to treatment and impact on the natural history of the disease will also contribute to 10 
the CT versus  US cost-effectiveness differences. 11 
 12 
Strengths and limitations 13 
This study appears to be the first to consider the cost-effectiveness of universal screening for 14 
FH at 1-2 years. The study compared the multiple screening options previously noted of 15 
interest,45 and recent local data were available to estimate several parameters. 16 
 17 
The persistent uncertainty around the sensitivity and specificity of different cholesterol 18 
theresholds,46 although considered in DSA (where we modelled the proportion of those with 19 
FH with cholesterol levels exceeding the threshold for genetic testing down to 62.5%) , is an 20 
important limitation of all work in this area, and sensitive to the definition of FH applied. 21 
Additional limitations in parameter estimation included the required extrapolation of 22 
treatment efficacy data from non-FH populations, beyond the duration of LMT trials, and 23 
beyond the intermediate outcomes of paediatric trials, as well as extrapolation of the CTT 24 
relative risk reduction estimates beyond primary events. Secondary CVD event risk estimates 25 
were limited by the time lapsed since their description and lack of adjustment for FH. FH-26 
specific utility data are few, and those applied (from non-FH populations) were drawn from 27 
studies that utilised a range of choice-based preference elicitation methods and samples 28 
(including non-UK-based samples).  As practical and ethical issues impact ability to 29 
overcome some of these limitations, assumptions are necessary if a decision is to be made on 30 
the basis of all information that is available.  Although the assumptions will impact on 31 
accuracy, several are common to previous models used in UK healthcare decision-making 32 
(e.g. the HTA for lipid modification in prevention of CVD, and the HTA that led to 33 
introduction of cluster testing for FH).  The assumptions applied may therefore be reasonable 34 
to UK healthcare decision-makers, and accuracy is potentially less of a concern if 35 
conservative assumptions lead to outcomes below a fixed willingness-to-pay threshold, as in 36 
this case. 37 
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 1 
The model structure necessarily followed a simplified version of treatment pathways and did 2 
not include additional potential inputs such as dietetics and management of statin-attributable 3 
diabetes, which appears in any case to be low in FH patients.47 48 The models also assumed no 4 
pre-existing CVD, which will not always be the case.49 Additional methodological limitations 5 
included the one-way modelling of uncertainties in DSA, when some could theoretically be 6 
realised in combination, and the ‘memoryless’ characteristic of Markov models which 7 
constrained modelling of accumulating CVD burden.  Regarding generalisability, economic 8 
evaluations require analyses to be contextualised, and the study is therefore of most direct 9 
relevance to the UK.  However, as cost-effectiveness of US has not previously been 10 
demonstrated for any setting, and cost-effectiveness in the UK is likely to be associated with 11 
cost-effectiveness elsewhere, the findings are likely to be of wider relevance, and may prompt 12 
review of the issue and analyses for non-UK contexts.  Under-diagnosis is a global concern, 13 
and universal screening is currently implemented, recommended and/or under consideration 14 
by relevant bodies in various jurisdictions.50-53  15 
 16 
Implications for research and practice 17 
2016 UK NSC review recommended against US for FH. Lack of demonstrated cost-18 
effectiveness was a concern, but also practical feasibility, acceptability, and lack of evidence 19 
that US would reduce morbidity and mortality.54 Feasibility of direct demonstration of impact 20 
on morbidity and mortality has been questioned, as the ethical and time demands of clinical 21 
endpoint trials are likely unachievable. However, the feasibility of US has now been 22 
demonstrated, in a study that also indicated acceptability among parents,24 and other studies 23 
have similarly found that participants generally consider such screening beneficial.39 55-57 24 
Together with our findings, which would conventionally (i.e. under the standard NICE 25 
threshold) support implementation of US, these studies support reconsideration of US. 26 
Cholesterol thresholds of alternative sensitivity/specificity (which may impact on US 27 
acceptability) could be considered in future analyses, when test performance at these 28 
thresholds has been described. 29 
 30 
Our analyses focused on screening at age 1-2 years, in view of recently demonstrated 31 
feasibility for this age-group.  Whilst this may be considered an appropriate age for screening 32 
in some contexts, others have shown interest in screening school-age children.50-53  The 33 
economic implications of screening at slightly higher ages are likely to be minimal, and 34 
screening at such ages could again be linked to other routine childhood healthcare 35 
attendances.  Vaccination uptake rates indicate that this would be unlikely to have a major 36 
impact on screening participation, at least in the UK.  A key issue for decisions about optimal 37 
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screening age is the outstanding uncertainty around the optimal age for treatment initiation.  It 1 
remains possible this may be around the time of school entry, or earlier.58  Once better 2 
understood, screening at an age that limits the need for ongoing review during a period of 3 
limited treatment options (i.e. when LMT is not effective and/or licensed) - and the potential 4 
associated anxiety – may be preferred.  It has also been suggest that screening would be best 5 
achieved whilst the sensitivity and specificity of cholesterol testing remains optimal.50    6 
  7 
 8 
Conclusions 9 
A sequential cholesterol screening-genetic testing plus RCT approach would be the most cost-10 
effective FH US strategy for the UK. Although a successful screening programme would 11 
reduce undiagnosed FH prevalence and therefore screening cost-effectiveness, sequential 12 
cholesterol screening-genetic testing plus RCT would remain cost-effective even if it 13 
continually achieved maximum plausible case ascertainment.     14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
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Legends 1 
 2 
Figure 1 – Decision tree and Markov model structures. 3 
(A) Decision tree used to estimate universal screening outcomes for each alternative. Outcomes 4 
were modelled separately for the FH-positive and FH-negative individuals in each cohort, according to 5 
the probabilities and formulae described in Table 1 and Supplementary File 2, respectively.   ‘Reflex’ 6 
testing (i.e. of samples already collected) applied where possible to minimize test requirements. 7 
 8 
(B) Markov model health states and connections. N.B. ‘Post-event’ states accessible from associated 9 
event states only. 10 
TC: total cholesterol; CVD: cardiovascular disease; MI: myocardial infarction; TIA: transient 11 
ischaemic attack; CHD: coronary heart disease 12 
 13 
 14 
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ACCEPTED MANUSCRIPTTable 1: Probabilities applied in calculation of decision tree outcomes. 
 
 
 
 
a1/250 = estimated FH prevalence; 0·95 = estimated proportion of those mutation-positive with total 
cholesterol ≥95th percentile (Wald et al, 2007, 2016); a,bEstimated prevalence figures recalculated for 
threshold analyses; cfull references in Supplementary File 9. 
FH: familial hypercholesterolaemia; TC: total cholesterol; US: universal screening. 
Probability Notation Value Calculation/rationale Referencesc 
All scenarios  
FH-positive (undiagnosed)a,b p(FH+) 0·0034 85% of estimated FH prevalence Akioyamen et al., 2017, 
Nordestgaard et al., 2013, 
Pedersen et al., 2010 
FH-negativeb p(FH-) 0·9966 1 – p(FH+)  
Mutation-positive given FH+ p(M+|FH+) 0·45 Probabilities reported from UK studies 
= 40.7% and 47.0%, within the range of 
values reported internationally (38.5-
57.0%).  
Futema et al., 2013, 
Graham et al., 2005, 
Damgaard et al., 2005, 
Klančar et al., 2015, 
Civeira et al., 2008   
Mutation-negative given FH+ p(M-|FH+) 0·55 1 - p(M+|FH+)  
Mutation-positive p(M+) 0·0019 (1/250)*p(M+|FH+)/0·95  
Mutation-positive given FH- p(M+|FH-) 9·51*10-5 p(M+) – (1/250)*p(M+|FH+)/p(FH-) 
(based on meta-analysis results 
indicative that ≥95% of M+ infants 
exhibit hypercholesterolaemia.  
Wald et al., 2007, 2016 
Mutation-negative given FH- p(M-|FH-) 1 - 9·51*10-5 1 – p(M+|FH-)  
First appointment attendance p(A1) 0·92 2015-16 UK 24-month vaccination 
coverage 
NHS Immunisation 
Statistics 
First test participation p(P1) 0·94 As per recent UK US study Wald et al., 2016 
Second appointment attendance p(A2) 0·92 2015-16 UK 24-month vaccination 
coverage  
NHS Immunisation 
Statistics 
Second test participation p(P2) 0·94 Willingness to participate in further 
screening reported in UK US study 
Wald et al., 2016 
Second elevated TC test 
following elevated first test 
p(TC2+|TC1+) 0·935 Pre-diagnosis duplication of elevated 
measurement recommended, in view of 
biological and analytical test variability 
Nordestgaard et al., 2013, 
Watts et al., 2015, NICE 
CG71, Neil, 1996 
Cholesterol-only screening scenario  
Positive TC tests given FH+ p(TC+|FH+) 0·88 This threshold applied as post-test 
probability (=0.78) reasonably low (and 
0.43 at next lowest threshold for which 
test performance figures described)  
Wald et al., 2007 
Positive TC tests given FH- p(TC+|FH-) 0·001 
Sequential genetic-TC and parallel TC-genetic screening scenarios  
Positive TC tests given FH+ p(TC+|FH+) 1 By definition  
Positive TC tests given FH- p(TC+|FH-) 0 By definition  
Negative TC tests among FH- p(TC-|FH-) 1 By definition  
Sequential TC-genetic screening scenario  
Positive TC tests among FH+ p(TC+|FH+) 0·96 Lowest threshold for which test 
performance described.  Found by UK 
US study to be above general 
population 95th percentile.  
Wald et al., 2007, 2016 
Positive TC tests among FH-a p(TC+|FH-) 0·045 0·05 – (1/250)  
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Table 2: Base case screening, treatment and health state costs 
 
 
 
 Cost/item 
(as listed) 
 
Details and referencesd 
Screening   
Nursing time:   
On local clinical expert advice, 30 min allocated for first 
US appointment, 15 min for second; 45 min for RCT 
consultation with index case, 30 min for consultation 
with relatives.  Time costed for band 7 nurse specialist a 
        - first US appointment £17.07 
        - second US appointment  £8.54 
        - index case consultation for CT £25.61 
        - initial relative CT appointment  £17.07 
NGS screen £263 2017-18 local laboratory NHS costs (Bristol Genetics 
Laboratory, 2017) Genetic test for known mutation £79 
Lipid profile test £3 2014 CG181 GDG estimate (in keeping with recently 
published values)   
Results/appointment invitation letter  £1.09 CPI-uplifted 2009 NICE FH costing template values 
Administrator time per letter £4.92 Time costed for band 5 administrator a 
Initial specialist review (paediatric) £316.70 2017-18 National Tariff first endocrinology outpatient 
review*mean MFF (NHS England)   Initial specialist review (adult) £239.96 
Treatment  
Average annual LMT (8-9 years) £10.31 
September 2017 Drug Tariff (NHS Business Services 
Authority)  Average annual LMT (10-17 years) £17.14 
Average annual LMT (adult) £204.11 
Lipid profile test £3 
2014 NICE CG181 GDG estimates (in keeping with 
recently published values)   Liver function tests £1 
Creatine kinase test £2 
Blood sampling appointment (paediatric) £5.01 20 min (paediatric) or 15 min (adult) of band 3 
phlebotomist time a  Blood sampling appointment (adult) £3.76 
Secondary care follow-up (paediatric) £156.73 2017-18 National Tariff follow-up endocrinology 
outpatient review*mean MFF (NHS England)   Secondary care follow-up (adult) £100.52 
Primary care follow-up (adult) £37.00 2017 face-to-face GP consultation cost (PSSRU)   
Health state costs (annual)  
Well and dead states £0 
CPI-adjusted CG181 estimates b c 
Stable angina £8280 
Post-stable angina £252.95 
Unstable angina £3694.70 
Post-unstable angina £405.78 
Myocardial infarction £3932.37 
Post-myocardial infarction £830.53 
Transient ischaemic attack £674.54 
Post-transient ischaemic attack £130.69 
Stroke £4394.53 
Post-stroke £163.37 
 
 
aStaff time costed using 2017-18 band midpoint salaries plus oncosts, assuming full-time working with 80% 
(nursing, phlebotomy) and 90% (administration) clinical time (NHS Staff Council, 2017; HMRC, 2017; NHS 
Business Services Authority, 2017); boriginally calculated based on guideline-recommended management; 
interim updates have been few, the main update being extension of stroke thrombolysis window from 3 to 4·5 
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hours (NICE CG68); cCPI used rather than health care specific index as figures available to more recent dates 
and higher overall, providing more conservative estimate; dfull references in Supplementary File 9.  
US: universal screening; (R)CT: (reverse) cascade testing; NGS: next generation sequencing; LMT: lipid 
modification therapy; GDG: guideline development group; CPI: consumer price index; FH: familial 
hypercholesterolaemia; NICE: National Institute for Health and Care Excellence; MFF: market forces factor; 
GP: general practitioner; PSSRU: Personal Social Services Research Unit. 
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Table 3: Summary of deterministic sensitivity analyses  
 
 
 
DSA-specific adjustment 
 
 
Rationale 
 
Referencesd 
All M+ defined as FH+  Both extent and duration of raised LDL-C influence CVD 
risk; hence M+ status associated with relatively high risk 
for given current LDL-C 
Khera et al., 2016, Damgaard et 
al., 2005 
RCT case yield/index = 0·5 Reflective of current CT achievement Hadfield et al., 2009, Kerr et al., 
2017, Marks, 2006 
RCT case yield/index = 6·1 Theoretical maximum achievable under current UK 
approach to CT.  
Morris et al., 2012 
RCT case yield/index = 8·6; 
probability relative M+ = 0·21 
Achieved in The Netherlands; theoretical maximum 
achievable in UK If first- to third- degree relatives 
screened unconditionally. Cases (n=2·5) identified with 
probability of second- versus third- degree relatives 
unclear, therefore analysed assuming all second-degree, 
repeated assuming all third-degree. 
Umans-Eckenhausen, 2001, 
Morris et al., 2012   
RCT case yield/index = 8·6; 
probability relative M+ = 0·31 
100% of diagnosed adults treated    
100% of diagnosed treated from 8 
years  
  
15% discontinue LMT at 10 years Potential LMT discontinuation/reduced adherence 
(reportedly, 84%+ treated, with ≥80% regime-adherent, 
at 10 years, but rates may fall over time)a 
Kusters et al., 2014, Galema-
Boers et al., 2014 
50% LDL-C reduction achieved 
with LMT  
NICE CG71 recommendation  
Estimated off-patent LMT costs 
applied 
Patents protecting rosuvastatin and ezetimibe due to 
expire this yearb 
September 2017 Drug Tariff, 
NHS Business Services 
Authority, Kerr et al., 2017 
Discount rate = 1·5%   
Discount rate = 5·0%   
CVD risks 90% of base case 
estimates 
It has not been possible to obtain unbiased estimates of 
untreated secondary event risks since LMT introduction.  
General population CVD risk has fallen in the meantime, 
and a continuing downward trajectory is predicted. 
Bhatnagar et al., 2016 
CVD risks 80% of base case 
estimates 
Undiagnosed cases treated at 
background rate 
Treatment prior to diagnosis plausiblec Nanchen et al., 2015, Carey et 
al., 2012, O’Keeffe et al., 2016, 
Fleetcroft et al., 2014 
Cholesterol test sensitivity in 
sequential cholesterol-genetic US 
strategy = 62·5% 
Recent finding detection rates with LDL-C threshold at 
approx. general population 95th percentile could be as low 
as 62·5% (lower using TC) (NB. n=6 mutation-positive 
children identified in study) 
 Futema et al., 2017 
Time for first US appointment 40 
min 
Expert clinician suggestion  
 
 
aIt was assumed that transition probabilities reverted to untreated values immediately on treatment 
discontinuation – likely conservative in view of treatment legacy effects.(Ford et al., 2016); bcurrent costs of 
simvastatin regimes with equivalent LDL-C-reducing potency used to estimate off-patent rosuvastatin costs.  
Off-patent ezetimibe cost estimated using value recently predicted by Kerr et al. (10% of current cost); c80% of 
secondary prevention patients, and 20, 30, 40 and 50% of those that reached 40, 50, 60 and 70 years, 
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respectively, were treated (regardless of diagnosed/undiagnosed status); dfull references in Supplementary File 
9. 
 DSA: deterministic sensitivity analysis; M+: mutation-positive; (R)CT: (reverse) cascade testing; LMT: lipid 
modifying therapy; LDL-C: low density lipoprotein cholesterol; CVD: cardiovascular disease; US: universal 
screening; NICE: National Institute for Health and Care Excellence; TC: total cholesterol 
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Table 4: Case yields, costs per diagnosis and cost-effectiveness of screening alternatives 
 
 
 
 
 
FH: familial hypercholesterolaemia; US: universal screening; RCT: reverse cascade testing; QALY: quality adjusted life year; ICER: incremental cost-effectiveness ratio; 
RCS: reverse cascade screening; ED: extendedly dominated; SD: strongly dominated 
 FH cases identified per 
10,000 screened  
Screening costs per diagnosis 
(£) 
  
 
QALYs Costs (£) 
ICER (£/QALY) 
US RCT total US RCT total 
 
 
versus no 
screening 
versus next 
lowest cost 
versus relevant 
alternative 
No screening 0 0 0 n/a n/a n/a 
  
992·2 225,983 - - - 
Cholesterol-only screening 22·38 0 22·38 11,788 n/a 11,788 
  
1,009·1 561,071 19,298 19,298 ED 
Sequential cholesterol-genetic 
screening  
24·41 0 24·41 13,785 n/a 13,785   1,010·7 640,288 21,872 50,184 ED 
Sequential cholesterol-genetic 
screening plus RCT 
24·41 15·38 39·79 13,785 1,110 8,886 
  
1,027·5 672,362 12,480 1,906 12,480 
Sequential genetic-cholesterol 
screening  
11·44 0 11·44 217,036 n/a 217,036 
  
1,000·7 2,745,892 283,799 SD SD 
Sequential genetic-cholesterol 
screening plus RCT 
11·44 19·67 31·11 217,036 1,110 80,519 
  
1,022·2 2,786,918 84,240 SD SD 
Parallel cholesterol-genetic screening 25·43 0 25·43 98,959 n/a 98,959 
  
1,011·5 2,823,343 131,635 SD SD 
Parallel cholesterol-genetic screening 
plus RCT 
25·43 19·67 45·10 98,959 1,110 56,279 
  
1,033·0 2,864,370 63,957 399,581 399,581 
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